IGHE and asthma: Omalizumab, a recombinant humanized anti-IgE monoclonal antibody, was the first biologic drug aimed at uncontrolled severe allergic asthma, which effectively reduced severe asthma exacerbations, improved asthma symptoms and lung function, and decreased the use of inhaled glucocorticosteroids with a long established (almost 20 years), favourable safety profile.